Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer's Disease related proteins
Stephanie R. Oatman, Joseph S. ReddyiD, Zachary QuicksalliD, Minerva M. CarrasquilloiD, Xue WangiD, Chia‐Chen LiuiD, Yu YamazakiiD, Thuy NguyeniD, Kimberly G. Malphrus, Michael G. HeckmaniD, Kristi Biswas, Kwangsik T. NhoiD, Matthew BakeriD, Yuka A. MartensiD, Na ZhaoiD, Jun Pyo KimiD, Shannon L. RisacheriD, Rosa RademakersiD, Andrew J. SaykiniD, Michael A. DetureiD, Melissa Erin MurrayiD, Takahisa KanekiyoiD, Alzheimer’s Disease Neuroimaging Initiative, Dennis W. DicksoniD, Guojun BuiD, , Nilüfer Ertekin‐TaneriD
Abstract
Alzheimers disease (AD) is neuropathologically characterized by amyloid-beta (A{beta}) plaques and neurofibrillary tangles. Main protein components of these hallmarks include A{beta}40, A{beta}42, tau, phospho-tau and APOE. With the exception of the APOE-{varepsilon}4 variant, genetic risk factors associated with brain biochemical measures of these proteins have yet to be characterized. We performed a genome-wide association study in brains of 441 AD patients for quantitative levels of these proteins collected from three distinct fractions reflecting soluble, membrane-bound and insoluble biochemical states. We identified 123 genome-wide significant associations at seven novel loci and the APOE locus. Genes and variants at these loci also associate with multiple AD- related measures, regulate gene expression, have cell-type specific enrichment, and roles in brain health and other neuropsychiatric diseases. Pathway analysis identified significant enrichment of shared and distinct biological pathways. Although all biochemical measures tested reflect proteins core to AD pathology, our results strongly suggest that each have unique genetic architecture and biological pathways that influence their specific biochemical states in the brain. Our novel approach of deep brain biochemical endophenotype GWAS has implications for pathophysiology of proteostasis in AD that can guide therapeutic discovery efforts focused on these proteins.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 24
- FWCI
- 4.41
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants
Vincent Damotte, Sven J. van der Lee, … Cornelia M. van Duijn·Alzheimer s & DementiaPeer-reviewed·May 18, 2021
- Connecting genomic and proteomic signatures of amyloid burden in the brain
Raquel Puerta, Itziar de Rojas, … Alzheimer’s Disease Neuroimaging Initiative·medRxiv·Sep 6, 2024
- Genetic Architecture of Plasma Amyloid and Tau Biomarkers in the Amish
Ping Wang, Dana Z. Jian, … Jonathan L. Haines·medRxiv·Oct 19, 2026
- Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort
Brenna Cholerton, Dana Godrich, … Thomas Jude Montine·PLoS GeneticsPeer-reviewed·Jun 29, 2026
- Genome and epigenome wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease risk
Robert Francis Hillary, Danni A. Gadd, … Riccardo Emilio Marioni·Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewed·Jan 1, 2022
- Integrative Epigenomic Landscape of Alzheimer's Disease Brains Reveals Oligodendrocyte Molecular Perturbations Associated with Tau
Stephanie R. Oatman, Joseph S. Reddy, … Nilüfer Ertekin‐Taner·Nature CommunicationsPeer-reviewed·Mar 3, 2026